KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Cost of Revenue (2016 - 2025)

Gilead Sciences (GILD) has disclosed Cost of Revenue for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 2.72% year-over-year to $1.6 billion, compared with a TTM value of $6.2 billion through Dec 2025, changed 0.27%, and an annual FY2025 reading of $6.2 billion, changed 0.27% over the prior year.
  • Cost of Revenue was $1.6 billion for Q4 2025 at Gilead Sciences, up from $1.6 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.6 billion in Q4 2021 and bottomed at $1.2 billion in Q3 2021.
  • Average Cost of Revenue over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2025.
  • The sharpest move saw Cost of Revenue skyrocketed 87.91% in 2021, then tumbled 46.86% in 2022.
  • Year by year, Cost of Revenue stood at $2.6 billion in 2021, then crashed by 46.86% to $1.4 billion in 2022, then soared by 49.71% to $2.1 billion in 2023, then fell by 24.35% to $1.6 billion in 2024, then increased by 2.72% to $1.6 billion in 2025.
  • Business Quant data shows Cost of Revenue for GILD at $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.